Anti-Infectives

Ramoplanin is highly active against drug-resistant C. difficile in vitro

Published in TB and Outbreaks Week, May 10th, 2005

The glycopeptide antibiotic ramoplanin is highly active against drug-resistant Clostridium difficile in vitro.

In a study from Spain, scientists evaluated the antimicrobial efficacy of ramoplanin - which "inhibits cell wall synthesis by acting at the level of lipid intermediate formation" - in C. difficile cultures.

"We included strains with reduced susceptibilities to vancomycin (vancomycin-intermediate [Vanⁱ] strains) or with resistance to metronidazole (Mtz^r), in order to assess the potential utility of ramoplanin for the treatment of C. difficile-associated diarrhea," explained T. Pelaez and coauthors at...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2005-05-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry